The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Ratain, Mark J.
Item TypeName
Concept Antineoplastic Agents
Concept Antineoplastic Agents, Hormonal
Concept Antineoplastic Agents, Phytogenic
Academic Article Phase I study of amonafide dosing based on acetylator phenotype.
Academic Article Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Academic Article Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Academic Article Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Academic Article Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Academic Article Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Academic Article Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Academic Article Keratoacanthomas and skin neoplasms associated with suramin therapy.
Academic Article Mineralocorticoid insufficiency due to suramin therapy.
Academic Article Pharmacodynamic modeling of prolonged administration of etoposide.
Academic Article Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Academic Article Data modifications to phase I study of suramin.
Academic Article Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Academic Article Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Academic Article Study of cohort-specific consent and patient control in phase I cancer trials.
Academic Article A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
Academic Article Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Academic Article Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
Academic Article Promising new agents in oncologic treatment.
Academic Article Oral chemotherapy: rationale and future directions.
Academic Article Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Academic Article Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
Academic Article Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Academic Article O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Academic Article Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
Academic Article Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Academic Article Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Academic Article Clinical pharmacology of camptothecins.
Academic Article Development of target-based antineoplastic agents.
Academic Article Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Academic Article Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
Academic Article Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
Academic Article Limited sampling model for area under the concentration time curve of total topotecan.
Academic Article Pharmacogenetics and cancer chemotherapy.
Academic Article Pharmacogenetics in cancer etiology and chemotherapy.
Academic Article Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Academic Article Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
Academic Article Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
Academic Article Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Academic Article Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Academic Article Update on pharmacogenetics in cancer chemotherapy.
Academic Article UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Academic Article A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Academic Article Elimination pathways of [14C]losoxantrone in four cancer patients.
Academic Article Endostatin: are the 2 years up yet?
Academic Article Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Academic Article Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Academic Article Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Academic Article Anticancer drug discovery and development throughout the world.
Academic Article Troxacitabine in patients with refractory leukemia.
Academic Article Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Academic Article Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Academic Article Pharmacogenetics in cancer treatment.
Academic Article Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Academic Article Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Academic Article In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
Academic Article Pharmacogenomics: road to anticancer therapeutics nirvana?
Academic Article A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Academic Article Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Academic Article Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Academic Article Clinical trial designs for cytostatic agents.
Academic Article Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Academic Article Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
Academic Article A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Academic Article A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Academic Article Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Academic Article Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Academic Article Randomized discontinuation design: application to cytostatic antineoplastic agents.
Academic Article Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Academic Article Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Academic Article Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Academic Article Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Academic Article Pharmacokinetic variability of anticancer agents.
Academic Article Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
Academic Article Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
Academic Article A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Academic Article From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Academic Article Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
Academic Article Finding the right dose.
Academic Article Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Academic Article Irinogenetics: what is the right star?
Academic Article Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Academic Article Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Academic Article Interpreting disparate responses to cancer therapy: the role of human population genetics.
Academic Article Effects of green tea compounds on irinotecan metabolism.
Academic Article Terminal ballistics of kinase inhibitors: there are no magic bullets.
Academic Article The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Academic Article A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Academic Article Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Academic Article Biomarkers in early cancer drug development: limited utility.
Academic Article Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
Academic Article The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Academic Article Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Academic Article Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Academic Article Etoposide pathway.
Academic Article The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Academic Article Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Academic Article Vascular endothelial growth factor pathway.
Academic Article Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Academic Article Evaluating the activity of temsirolimus in neuroendocrine cancer.
Academic Article Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
Academic Article Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
Academic Article Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Academic Article In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Academic Article A phase I study of continuous infusion cilengitide in patients with solid tumors.
Academic Article The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Academic Article Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Academic Article What is the choice of treatment for hairy cell leukemia?
Academic Article Flushing oral oncology drugs down the toilet.
Academic Article A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Academic Article Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Academic Article Current dilemmas in carboplatin dosing.
Academic Article Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Academic Article Optimising the design of phase II oncology trials: the importance of randomisation.
Academic Article Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Academic Article Bar the windows but open the door to randomization.
Academic Article The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
Academic Article A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
Academic Article Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
Academic Article Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
Academic Article Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Academic Article Merrill Jon Egorin, MD, 1948-2010.
Academic Article The treatment of hairy cell leukemia: an update.
Academic Article Randomized phase II trials: a long-term investment with promising returns.
Academic Article Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
Academic Article Importance of food effects for oral oncology drugs.
Academic Article Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Academic Article Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Academic Article Cancer chemotherapy and skin changes.
Academic Article Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
Academic Article Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
Academic Article Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Academic Article A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Academic Article Pharmacogenetics and pharmacogenomics of anticancer agents.
Academic Article Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Academic Article Individualizing dosing of irinotecan.
Academic Article Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Academic Article Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
Academic Article Perceptions of cancer patients and their physicians involved in phase I trials.
Academic Article Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
Academic Article Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Academic Article Body surface area as a determinant of pharmacokinetics and drug dosing.
Academic Article Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Academic Article Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Academic Article Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Academic Article A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Academic Article Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
Academic Article Measuring response in a post-RECIST world: from black and white to shades of grey.
Academic Article The role of pharmacogenetics in cancer therapeutics.
Academic Article Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Academic Article Pharmacodynamics in cancer therapy.
Academic Article Rapamycin: something old, something new, sometimes borrowed and now renewed.
Academic Article Pharmacogenetic pathway analysis of irinotecan.
Academic Article A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Academic Article Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Academic Article Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Academic Article Value-based insurance design in oncology.
Academic Article Opportunities and challenges in the development of experimental drug combinations for cancer.
Academic Article Oncology micro-cap stocks: caveat emptor!
Academic Article Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
Academic Article Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Academic Article Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Academic Article Unsupported off-label chemotherapy in metastatic colon cancer.
Academic Article Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Academic Article Cancer pharmacogenomics: strategies and challenges.
Academic Article Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
Academic Article Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
Academic Article Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Academic Article The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Academic Article Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Academic Article Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Academic Article Targeted therapies: redefining the primary objective of phase I oncology trials.
Academic Article Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
Academic Article Incorporating biomarkers into drug labeling.
Academic Article Challenges in interpreting the evidence for genetic predictors of ototoxicity.
Academic Article Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Academic Article Are drug labels static or dynamic?
Academic Article Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
Academic Article Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Academic Article Vemurafenib oral bioavailability: an insoluble problem.
Academic Article Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
Academic Article A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Academic Article Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
Academic Article First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Academic Article Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
Academic Article Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Academic Article Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
Academic Article Drug-Drug Interactions With Oral Antineoplastic Agents.
Academic Article Food Effect Studies for Oncology Drug Products.
Academic Article Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Academic Article Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
Academic Article Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Academic Article Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Academic Article Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Academic Article The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Academic Article Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Academic Article Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Academic Article Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
Academic Article Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Academic Article A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
Academic Article Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Academic Article A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
Academic Article Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Academic Article Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Academic Article Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
Academic Article Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.
Academic Article Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
Academic Article Negative innovation: when patents are bad for patients.
Academic Article Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
Academic Article Dose Optimization of Pembrolizumab: Less May Be More.
Academic Article Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Academic Article Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Concept Antineoplastic Agents, Immunological
Academic Article Special designations and the US Food and Drug Administration's "dual mandate".
Search Criteria
  • Antineoplastic Agents